Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 4 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Inventage Lab Inc. is currently managing 8 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 8 actions are distributed among 8 distinct examiners, which means that every single pending case is being reviewed by a different individual. This high level of examiner diversity requires a prosecution strategy that can adapt to eight different personal styles and requirements. The portfolio is spread across 4 distinct art units, indicating a range of biological or pharmaceutical classifications.
SCHLIENTZ, NATHAN W is the busiest examiner identified, though he is only responsible for 1 pending office action. Because each of the 8 distinct examiners manages exactly 1 pending office action, no single examiner has a dominant influence over the portfolio. Practitioners must prepare for 8 unique sets of feedback across the 4 distinct art units. This distribution of 8 pending office actions suggests that the company is pursuing multiple technical advancements within its field.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (38%) |
| Double-patenting + other | 1 (12%) |
| Multi-statute (no §101) | 4 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHLIENTZ, NATHAN W | 1 | 41.3% | -18.9% |
| KUCKLA, ANNA GRACE | 1 | 53.2% | +54.1% |
| BHATIA, ANSHU | 1 | 84.2% | +17.2% |
| TRAN, SUSAN T | 1 | 62.8% | +35.1% |
| SHOMER, ISAAC | 1 | 63.2% | +30.4% |
| AZPURU, CARLOS A | 1 | 83.8% | +10.7% |
| PURDY, KYLE A | 1 | 41.0% | +35.9% |
| ATKINSON, JOSHUA ALEXANDER | 1 | 52.4% | +26.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18284981 | METHOD FOR PREPARING MICROPARTICLES CONTAINING POORLY SOLUBLE DRUGS | TRAN, SUSAN T | 17d overdue |
| 18976930 | NOVEL LONG-ACTING INJECTABLE COMPOSITION FOR PREVENTING OR TREATING ANDROGENETIC ALOPECIA CONTAINING FINASTERIDE | KUCKLA, ANNA GRACE | — |
| 18291366 | NANO LIPID PARTICLES MANUFACTURING CHIP, NANO LIPID PARTICLES MANUFACTURING SYSTEM HAVING THE SAME, AND NANO LIPID PARTICLES MANUFACTURING METHOD | BHATIA, ANSHU | — |
| 18325567 | SUSTAINED FORMULATION FOR PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASE CONTAINING NALTREXONE AND METHOD USING THE SAME | AZPURU, CARLOS A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17723155 | SUSTAINED-RELEASE MICROPARTICLES FOR SUSTAINED RELEASE OF DRUG | PURDY, KYLE A | 25d overdue |
| 18284981 | METHOD FOR PREPARING MICROPARTICLES CONTAINING POORLY SOLUBLE DRUGS | TRAN, SUSAN T | 17d overdue |
| 17762701 | SUSTAINED-RELEASE MICROPARTICLES FOR SUSTAINED RELEASE OF DRUG | ATKINSON, JOSHUA ALEXANDER | 6d |
| 18281915 | LIPID NANOPARTICLE PREPARATION METHOD AND PREPARATION APPARATUS THEREFOR | SHOMER, ISAAC | 71d |
| 18976930 | NOVEL LONG-ACTING INJECTABLE COMPOSITION FOR PREVENTING OR TREATING ANDROGENETIC ALOPECIA CONTAINING FINASTERIDE | KUCKLA, ANNA GRACE | — |
| 18291366 | NANO LIPID PARTICLES MANUFACTURING CHIP, NANO LIPID PARTICLES MANUFACTURING SYSTEM HAVING THE SAME, AND NANO LIPID PARTICLES MANUFACTURING METHOD | BHATIA, ANSHU | — |
| 18325567 | SUSTAINED FORMULATION FOR PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASE CONTAINING NALTREXONE AND METHOD USING THE SAME | AZPURU, CARLOS A | — |
| Art Unit | Apps |
|---|---|
| 1612 | 2 |
| 1615 | 1 |
| 1617 | 1 |
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18992017 | SUSTAINED-RELEASE INJECTABLE COMPOSITION CONTAINING DUTASTERIDE | SCHLIENTZ, NATHAN W | — | §103DP | Non-Final OA | — | Pending | Jan 07, 2025 |
| 18976930 | NOVEL LONG-ACTING INJECTABLE COMPOSITION FOR PREVENTING OR TREATING ANDROGENETIC ALOPECIA CONTAINING FINASTERIDE | KUCKLA, ANNA GRACE | — | §102§103§112 | Non-Final OA | — | Pending | Dec 11, 2024 |
| 18291366 | NANO LIPID PARTICLES MANUFACTURING CHIP, NANO LIPID PARTICLES MANUFACTURING SYSTEM HAVING THE SAME, AND NANO LIPID PARTICLES MANUFACTURING METHOD | BHATIA, ANSHU | — | §102§103§112 | Non-Final OA | — | Pending | Jan 23, 2024 |
| 18284981 | METHOD FOR PREPARING MICROPARTICLES CONTAINING POORLY SOLUBLE DRUGS | TRAN, SUSAN T | 1615 | §102§103§112 | Final Rejection | 17d overdue | Pending | Sep 29, 2023 |
| 18281915 | LIPID NANOPARTICLE PREPARATION METHOD AND PREPARATION APPARATUS THEREFOR | SHOMER, ISAAC | 1612 | §103 | Final Rejection | 71d | Pending | Sep 13, 2023 |
| 18325567 | SUSTAINED FORMULATION FOR PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASE CONTAINING NALTREXONE AND METHOD USING THE SAME | AZPURU, CARLOS A | 1617 | §103§112 | Non-Final OA | — | Pending | May 30, 2023 |
| 17723155 | SUSTAINED-RELEASE MICROPARTICLES FOR SUSTAINED RELEASE OF DRUG | PURDY, KYLE A | 1611 | §103 | Final Rejection | 25d overdue | Pending | Apr 18, 2022 |
| 17762701 | SUSTAINED-RELEASE MICROPARTICLES FOR SUSTAINED RELEASE OF DRUG | ATKINSON, JOSHUA ALEXANDER | 1612 | §103Other | Non-Final OA | 6d | Pending | Mar 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial